Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss
Medtronic Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss increased by 3.0% to $7.26B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $6.82B to $7.26B. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss shows relatively stable performance with a -1.1% CAGR.
Analysis
How to read this metric
An increase suggests capital deployment into fixed-income assets, while a decrease may indicate portfolio liquidation or maturation.
Detailed definition
This reflects the amortized cost basis of debt securities classified as available-for-sale, adjusted for credit losses b...
Peer comparison
Common in insurance and banking sectors; peers report this under 'Investments' in the balance sheet.
other_debt_securities_available_for_sale_amortized_cost__1e72d5Historical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.14B | $7.50B | $7.74B | $7.80B | $7.13B | $7.03B | $7.09B | $6.98B | $6.75B | $6.89B | $6.80B | $6.91B | $6.97B | $6.69B | $6.71B | $6.82B | $6.83B | $6.91B | $7.05B | $7.26B |
| QoQ Change | — | +4.9% | +3.3% | +0.7% | -8.5% | -1.4% | +0.9% | -1.6% | -3.3% | +2.1% | -1.3% | +1.7% | +0.8% | -4.0% | +0.3% | +1.6% | +0.2% | +1.2% | +1.9% | +3.0% |
| YoY Change | — | — | — | — | -0.2% | -6.2% | -8.4% | -10.5% | -5.4% | -2.0% | -4.2% | -0.9% | +3.3% | -2.9% | -1.3% | -1.4% | -2.0% | +3.3% | +5.0% | +6.5% |
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at Other Companies
Frequently Asked Questions
- What is Medtronic's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Medtronic (MDT) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $7.26B in Q4 2025.
- How has Medtronic's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss changed year-over-year?
- Medtronic's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss increased by 6.5% year-over-year, from $6.82B to $7.26B.
- What is the long-term trend for Medtronic's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Over 4 years (2021 to 2025), Medtronic's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss has grown at a -1.1% compound annual growth rate (CAGR), from $7.14B to $6.83B.
- What does debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss mean?
- The historical cost of debt investments held for potential sale, adjusted for credit losses.